SEC 13F Intelligence

Highvista Strategies LLC / PCVX

Highvista Strategies LLC’s Vaxcyte Inc Position

Does Highvista Strategies LLC own Vaxcyte Inc (PCVX)? Yes — 124.6K shares worth $7M (+2.00% of its 13F portfolio) as of Q1 2026, up from 114.0K shares the prior filed quarter.

Position Value
$7M
Q1 2026
Shares
124.6K
% of Portfolio
+2.00%
Quarters Held
16
currently held

Position History PCVX

Reported value by quarter
Q2 ’22: $609,000Q2 ’22Q3 ’22: $501,000Q4 ’22: $940,108Q4 ’22Q1 ’23: $734,833Q2 ’23: $727,176Q2 ’23Q3 ’23: $573,423Q4 ’23: $585,359Q4 ’23Q1 ’24: $636,718Q2 ’24: $2MQ2 ’24Q3 ’24: $5MQ4 ’24: $4MQ4 ’24Q1 ’25: $1MQ2 ’25: $1MQ2 ’25Q3 ’25: $3MQ4 ’25: $5MQ4 ’25Q1 ’26: $7Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026124.6K$7M+2.00%
Q4 2025114.0K$5M+1.36%
Q3 202586.8K$3M+0.77%
Q2 202533.5K$1M+0.40%
Q1 202533.1K$1M+0.48%
Q4 202444.7K$4M+1.36%
Q3 202444.7K$5M+1.76%
Q2 202432.3K$2M+0.89%
Q1 20249.3K$636,718+0.23%
Q4 20239.3K$585,359+0.21%
Q3 202311.2K$573,423+0.27%
Q2 202314.6K$727,176+0.33%
Q1 202319.6K$734,833+0.60%
Q4 202219.6K$940,108+0.56%
Q3 202220.9K$501,000+0.29%
Q2 202228.0K$609,000+0.37%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Highvista Strategies LLC’s full portfolio or all institutional holders of PCVX.